2023Äê2ÔÂ15ÈÕ£¬£¬£¬£¬£¬£¬ÑÎËá¿­ÆÕÀ­Éú»ñµÃ¹ú¼ÒÒ©Æ·¼àÊÓÖÎÀí¾Ö£¨NMPA£©Åú×¼£¬£¬£¬£¬£¬£¬ÓÃÓÚÊ®¶þÖ¸³¦À£Ññ£¨DU£©ºÍ·´Á÷ÐÔʳ¹ÜÑ×£¨RE£©µÄÖÎÁÆ£¬£¬£¬£¬£¬£¬³ÉΪº£ÄÚΨһͬʱ»ñÅú˫˳Ӧ֢µÄP-CAB£¬£¬£¬£¬£¬£¬ÔÚÒѽÒÏþµÄÊ®¶þÖ¸³¦À£ÑñµÄ¢ò¡¢¢óÆÚÑо¿ºÍ·´Á÷ÐÔʳ¹ÜÑ×¢óÆÚÑо¿ÖУ¬£¬£¬£¬£¬£¬20 mg ÑÎËá¿­ÆÕÀ­ÉúÖÎÁÆÊ®¶þÖ¸³¦À£ÑñºÍ·´Á÷ÐÔʳ¹ÜÑ×µÄÁÆЧºÍÄÍÊÜÐÔ»ñµÃ֤ʵ^2-4£¬£¬£¬£¬£¬£¬Ñо¿Ð§¹ûÖ§³ÖÑÎËá¿­ÆÕÀ­ÉúÓÃÓÚÖÎÁÆÊ®¶þÖ¸³¦À£ÑñºÍ·´Á÷ÐÔʳ¹ÜÑס£¡£¡£¡£¡£±¾´Î½ÒÏþµÄÑÎËá¿­ÆÕÀ­Éúµ¥´ÎµÝÔö¢ñÆÚÑо¿Êý¾Ý£¬£¬£¬£¬£¬£¬Ñо¿Ñ¡È¡À¼Ë÷À­ßò×÷ΪÑôÐÔ±ÈÕÕÒ©£¬£¬£¬£¬£¬£¬Í¬Ê±½ÏÁ¿ÆÊÎöÁËÑÎËá¿­ÆÕÀ­ÉúºÍÀ¼Ë÷À­ßòµÄÒ©´ú¶¯Á¦Ñ§£¨PK£©ºÍҩЧ¶¯Á¦Ñ§£¨PK£©ÌØÕ÷¡£¡£¡£¡£¡£

±¾Ñо¿ÎªËæ»ú¡¢Ë«Ã¤¡¢ÑôÐÔÒ©/ο½å¼Á±ÈÕÕÑо¿£¬£¬£¬£¬£¬£¬Èë×éÄêËêΪ18 ~45 ÖÜË꣨º¬18 ºÍ45 ÖÜË꣩µÄ¿µ½¡³ÉÄêÊÜÊÔÕߣ¬£¬£¬£¬£¬£¬¹²Éè5 ¸öÑÎËá¿­ÆÕÀ­Éú¼ÁÁ¿×飨5mg¡¢10mg¡¢20mg¡¢40mg¡¢60mg£©¡£¡£¡£¡£¡£Ç°8λÊÜÊÔÕ߶¼ÄÉÈë5mg¼ÁÁ¿×é½ÓÊÜÑÎËá¿­ÆÕÀ­Éú£¬£¬£¬£¬£¬£¬ºóÐøÊÜÊÔÕßƾ֤ǰһ¼ÁÁ¿×éµÄÄÍÊÜÐÔÇéÐΣ¬£¬£¬£¬£¬£¬ÒÀ´Î½øÈë10mg¡¢20mg¡¢40mg¡¢60mg¼ÁÁ¿×飬£¬£¬£¬£¬£¬Ã¿×éÈë×é12ÀýÊÜÊÔÕßÒÔ4:1:1µÄ±ÈÀýËæ»ú½ÓÊÜÑÎËá¿­ÆÕÀ­Éú¡¢30mgÀ¼Ë÷À­ßòºÍο½å¼Á¡£¡£¡£¡£¡£Ö÷ÒªÑо¿ÖÕµãΪµ¥´Î¿Ú·þÑÎËá¿­ÆÕÀ­ÉúµÄÇå¾²ÐÔºÍÄÍÊÜÐÔ¡£¡£¡£¡£¡£´ÎÒªÑо¿ÖÕµãΪµ¥´Î¿Ú·þÑÎËá¿­ÆÕÀ­ÉúµÄÈËÌåÒ©´ú¶¯Á¦Ñ§ºÍҩЧ¶¯Á¦Ñ§ÌØÕ÷¡£¡£¡£¡£¡£

Ñо¿¹²Èë×é56ÀýÊÜÊÔÕߣ¬£¬£¬£¬£¬£¬½ÓÊÜÑÎËá¿­ÆÕÀ­Éú¡¢30 mg À¼Ë÷À­ßòºÍο½å¼ÁµÄÊÜÊÔÕßÑо¿Ê±´ú²»Á¼ÊÂÎñµÄ±¬·¢ÂÊ»®·ÖΪ32.5%£¬£¬£¬£¬£¬£¬50.0%£¬£¬£¬£¬£¬£¬37.5%£¬£¬£¬£¬£¬£¬ÑÏÖØˮƽ¶¼ÎªÇáÖжÈ£¬£¬£¬£¬£¬£¬ÎÞÑÏÖز»Á¼ÊÂÎñ±¬·¢¡£¡£¡£¡£¡£µ¥´Î¿Ú·þ5mg¡¢10mg¡¢20mg¡¢40mg ºÍ60mgÑÎËá¿­ÆÕÀ­Éúºó£¬£¬£¬£¬£¬£¬ÆäT_maxµÄÖÐλÊýΪ1.25~1.75h£¬£¬£¬£¬£¬£¬t_1/2 ¾ùÖµ¹æģΪ6.00~7.17h£¬£¬£¬£¬£¬£¬C_max£¨Æ½¾ùÖµ¹æÄ££º5.83 ÖÁ 89.3 ng/mL£©ºÍAUC_0-¡Þ£¨Æ½¾ùÖµ¹æÄ££º54.3 ÖÁ 785 h¡¤ng/mL£©ËæןøÒ©¼ÁÁ¿µÄÔöÌí¶øÔöÌí¡£¡£¡£¡£¡£¸øÓè30 mgÀ¼Ë÷À­ßòºó£¬£¬£¬£¬£¬£¬ÆäT_maxµÄÖÐλÊýΪ1.5h£¬£¬£¬£¬£¬£¬t_1/2¾ùֵΪ2.00h¡£¡£¡£¡£¡£ÑÎËá¿­ÆÕÀ­ÉúµÄ°ëË¥ÆÚ³¤ÓÚÀ¼Ë÷À­ßò¡£¡£¡£¡£¡£

¸øÓèÑÎËá¿­ÆÕÀ­ÉúºÍÀ¼Ë÷À­ßòºóθËápHֵѸËÙÉÏÉý£¬£¬£¬£¬£¬£¬µ¥´Î¿Ú·þÀ¼Ë÷À­ßòµÄÒÖËáЧ¹û½öά³ÖÔ¼12h£¬£¬£¬£¬£¬£¬ËæºóÖð½¥Ï½µ£¬£¬£¬£¬£¬£¬Ò¹¼äθËáÒÖÖÆЧ¹û²î¡£¡£¡£¡£¡£ÑÎËá¿­ÆÕÀ­Éú¹ØÓÚθËáµÄÒÖÖÆ×÷Ó÷ºÆð¼ÁÁ¿ÒÀÀµÐÔ£¬£¬£¬£¬£¬£¬40-60 mg ÑÎËá¿­ÆÕÀ­ÉúµÄÒÖËáЧ¹ûÇ¿ÓÚ10-20 mg¡£¡£¡£¡£¡£µ¥´Î¿Ú·þ20mg-60mgÑÎËá¿­ÆÕÀ­Éú16¸öСʱºóθËápHÖµÈÔά³ÖÔÚ6ÒÔÉÏ£¬£¬£¬£¬£¬£¬Í¬Ê±ÊÜÊÔÕß24СʱÄÚθËápHÖµ´óÓÚ3µÄʱ¼ä°Ù·Ö±È£¨pH >3 HTR£©£¬£¬£¬£¬£¬£¬pH >4 HTRºÍpH >5 HTR¶¼ÓÅÓÚ30 mgÀ¼Ë÷À­ßò¡£¡£¡£¡£¡£

ͼ1. ·þÓÃ5mg-60mg ÑÎËá¿­ÆÕÀ­Éú¡¢30mg À¼Ë÷À­ßò»òο½å¼Áºó£¬£¬£¬£¬£¬£¬£¨A£©24hÄÚƽ¾ùθÄÚpH -ʱ¼äÇúÏߣ¬£¬£¬£¬£¬£¬£¨B£©48hÄÚƽ¾ùθÄÚpH -ʱ¼äÇúÏß

±í1. ¿Ú·þÑÎËá¿­ÆÕÀ­Éú¡¢À¼Ë÷À­ßò¼°Î¿½å¼Áºó£¬£¬£¬£¬£¬£¬24h¼°Ò¹¼äƽ¾ùθpH>3¡¢pH>4¡¢pH>5 ʱ¼ä°Ù·Ö±È»ã×ÜЧ¹û

¿µ½¡ÊÜÊÔÕßµ¥´Î¿Ú·þ5-60mgÑÎËá¿­ÆÕÀ­ÉúµÄÄÍÊÜÐÔÓÅÒ죬£¬£¬£¬£¬£¬20 mg¼ÁÁ¿Ï¿ɱ¬·¢ÓÅÓÚ30mg À¼Ë÷À­ßòµÄÎȹ̡¢³¤ÆÚµÄÒÖËáЧ¹û¡£¡£¡£¡£¡£

ÉóÅúÂ룺NP-MA-20230921-CN-KEV-00003

²Î¿¼ÎÄÏ×

1. 1.???? Sufeng?Zhou, et al. Keverprazan, a novel potassium-competitive acid blocker: Single ascending dose safety, tolerability, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Eur J Pharm Sci. 2023 Sep 2;106578. doi: 10.1016/j.ejps.2023.106578.

2. 2.???? Songfeng Chen, et al. The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive esophagitis: a phase III, randomised, double-blind multicentre study. Aliment Pharmacol Ther. 2022 Jun;55(12):1524-1533. doi: 10.1111/apt.16959.

3. 3.???? Nian-di Tan, et al. Efficacy of keverprazan for duodenal ulcer: A phase II randomized, double-blind, parallel-controlled trial. J Gastroenterol Hepatol. 2022 Nov;37(11):2060-2066. doi: 10.1111/jgh.16000.

4. 4.???? Nian-di Tan, et al. Efficacy and safety of keverprazan compared to lansoprazole in the treatment of duodenal ulcer: a phase III, randomised, double-blind, multicentre trial. Clin Transl Gastroenterol. 2023 May 29. doi: 10.14309/ctg.0000000000000602.